Do you use immune checkpoint inhibitors in NSCLC patients with pre-existing, well-controlled autoimmune disease?

While there is limited data on the use of PD1 inhibitors in patients with pre-existing autoimmune conditions; in patients with metastatic NSCLC with limited options, it warrants consideration. This is obviously a high risk population to treat and close monitoring and co-ordinated care with specialis...

This is a great question - there should not be a blanket withholding of checkpoint inhibitor therapy for patients with pre-existing autoimmune diseases.

If immune checkpoint inhibitors (ICIs) are the next best option for the patient's malignancy, having control of the pre-existing autoimmune disease...